Physician profile
Qi Che
NPI 1447429212
$5,702.70
in general payments reported to CMS, 2019-2025
23 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $1,050 · 2021: $703 · 2022: $485 · 2023: $568 · 2024: $1,162 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.95 |
| Education | $146.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,179.03 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $846.54 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $460.45 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $411.03 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $364.40 | 2022-2025 | Tarpeyo |
| Amgen INC. | $346.08 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $316.18 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $274.51 | 2019-2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $267.82 | 2021-2025 | |
| Travere Therapeutics, INC. | $204.31 | 2022-2025 | |
| Lilly USA, LLC | $179.18 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $160.16 | 2022-2024 | Jesduvroq, Benlysta |
| Vifor Pharma, INC. | $148.80 | 2019-2021 | |
| Horizon Therapeutics Plc | $130.81 | 2022-2023 | Krystexxa |
| Novo Nordisk INC | $68.88 | 2025 | Ozempic |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $65.14 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $58.22 | 2019-2023 | |
| Scpharmaceuticals INC. | $51.39 | 2025 | |
| Aurinia Pharma U.S., INC. | $46.89 | 2023-2024 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $44.00 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $38.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $20.08 | 2020 | |
| Akebia Therapeutics INC | $19.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qi Che listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.